NCT03868345 is a clinical trial in ALS, sponsored by Barrow Neurological Institute.

Who is sponsoring NCT03868345?

NCT03868345 is sponsored by Barrow Neurological Institute.

What condition does NCT03868345 study?

NCT03868345 studies ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease.

Is NCT03868345 still recruiting?

NCT03868345 is currently completed. Last updated 9 March 2023.

Last reviewed 2023-03-09 · How we verify

NCT03868345

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Speech Analysis in ALS Patients

Completed Last updated 9 March 2023

What this trial tests

trial in ALS in 26 participants. Completed in 30 April 2021.

Timeline

18 February 2019

Primary endpoint
30 April 2021

30 April 2021

Quick facts

Lead sponsor	Barrow Neurological Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	26
Start date	18 February 2019
Primary completion	30 April 2021
Estimated completion	30 April 2021
Sites	1 location across United States

Conditions studied

ALS — all drugs for ALS →
Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →
Lou Gehrig Disease — all drugs for Lou Gehrig Disease →

Sponsor

Barrow Neurological Institute

Who can join

21 and older, any sex, with ALS or Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year. Every three months, patients will undergo a series of cognitive and basic clinical outcomes tests. In addition, participants will take home a study-provided tablet on which they will complete weekly speech recording activities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for ALS

Currently open trials in the same condition.

NCT07460037 — Chinese-Specific Speech Imagery Coding Using High-Density ECoG · NA · recruiting
NCT07006571 — At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis · NA · recruiting
NCT07193953 — Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) · Phase 1 · recruiting
NCT06735014 — Multicenter ALS Imaging Study · recruiting
NCT06511934 — Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01) · NA · recruiting

Other Barrow Neurological Institute trials

Trials by the same sponsor.

NCT02819765 — Deep Phenotyping in Patients With ALS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03868345 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barrow Neurological Institute
Last refreshed: 9 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03868345.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing